HOOKHOOKIPA Pharma Inc.

Nasdaq www.hookipapharma.com


$ 0.52 $ -0.04 (-7.96 %)    

Monday, 08-Jul-2024 12:47:45 EDT
QQQ $ 496.64 $ 0.11 (0.02 %)
DIA $ 392.80 $ -0.90 (-0.23 %)
SPY $ 554.75 $ -0.15 (-0.03 %)
TLT $ 92.73 $ 0.30 (0.32 %)
GLD $ 218.06 $ -1.59 (-0.72 %)
$ 0.565
$ 0.52
$ 0.00 x 0
$ 0.00 x 0
$ 0.50 - $ 0.53
$ 0.41 - $ 1.13
432,187
na
55.91M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-22-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 05-20-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-hookipa-pharma-hook-stock-is-volatile-today

HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock sp...

 hookipa-pharma-to-implement-1-for-10-reverse-stock-split-effective-july-9-2024

HOOKIPA Pharma Inc. (NASDAQ:HOOK, ", HOOKIPA", )))), a company developing a new class of immunotherapeutics based on it...

 hc-wainwright--co-maintains-buy-on-hookipa-pharma-raises-price-target-to-6

HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and raises the price target from...

 hookipa-pharma-announces-phase-2-results-for-hb-200-combined-with-pembrolizumab-in-hpv16-head-and-neck-cancer

Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated wi...

 rbc-capital-reiterates-outperform-on-hookipa-pharma-maintains-5-price-target

RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.

 hookipa-pharma-q1-2024-gaap-eps-011-beats-010-estimate-sales-36599m-beat-2800m-estimate

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.10...

 hc-wainwright--co-maintains-buy-on-hookipa-pharma-lowers-price-target-to-5

HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from...

 why-is-penny-stock-hookipa-pharma-trading-higher-on-wednesday

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about ...

 roches-lymphoma-drug-with-chemo-extends-survival-in-pretreated-patients

Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + G...

 rbc-capital-reiterates-outperform-on-hookipa-pharma-maintains-5-price-target

RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.